Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris: the SEROCOV cohort study.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 05 2022
Historique:
received: 08 10 2021
accepted: 30 03 2022
entrez: 4 5 2022
pubmed: 5 5 2022
medline: 7 5 2022
Statut: epublish

Résumé

With the COVID-19 pandemic, documenting whether health care workers (HCWs) are at increased risk of SARS-CoV-2 contamination and identifying risk factors is of major concern. In this multicenter prospective cohort study, HCWs from frontline departments were included in March and April 2020 and followed for 3 months. SARS-CoV-2 serology was performed at month 0 (M0), M1, and M3 and RT-PCR in case of symptoms. The primary outcome was laboratory-confirmed SARS-CoV-2 infection at M3. Risk factors of laboratory-confirmed SARS-CoV-2 infection at M3 were identified by multivariate logistic regression. Among 1062 HCWs (median [interquartile range] age, 33 [28-42] years; 758 [71.4%] women; 321 [30.2%] physicians), the cumulative incidence of SARS-CoV-2 infection at M3 was 14.6% (95% confidence interval [CI] [12.5; 16.9]). Risk factors were the working department specialty, with increased risk for intensive care units (odds ratio 1.80, 95% CI [0.38; 8.58]), emergency departments (3.91 [0.83; 18.43]) and infectious diseases departments (4.22 [0.92; 18.28]); current smoking was associated with reduced risk (0.36 [0.21; 0.63]). Age, sex, professional category, number of years of experience in the job or department, and public transportation use were not significantly associated with laboratory-confirmed SARS-CoV-2 infection at M3. The rate of SARS-CoV-2 infection in frontline HCWs was 14.6% at the end of the first COVID-19 wave in Paris and occurred mainly early. The study argues for an origin of professional in addition to private life contamination and therefore including HCWs in the first-line vaccination target population. It also highlights that smokers were at lower risk.Trial registration The study has been registered on ClinicalTrials.gov: NCT04304690 first registered on 11/03/2020.

Identifiants

pubmed: 35508515
doi: 10.1038/s41598-022-10945-y
pii: 10.1038/s41598-022-10945-y
pmc: PMC9068621
doi:

Banques de données

ClinicalTrials.gov
['NCT04304690']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7211

Informations de copyright

© 2022. The Author(s).

Références

Eur Respir J. 2020 Jul 16;56(1):
pubmed: 32430431
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
JAMA. 2020 Sep 1;324(9):893-895
pubmed: 32780804
JAMA Intern Med. 2020 Dec 1;180(12):1707-1709
pubmed: 32780100
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Clin Infect Dis. 2021 May 4;72(9):1645-1648
pubmed: 32628750
JAMA. 2020 Nov 3;324(17):1781-1782
pubmed: 32940635
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
Nicotine Tob Res. 2021 Aug 4;23(8):1436-1440
pubmed: 32964233
Clin Infect Dis. 2021 Nov 2;73(9):e2853-e2860
pubmed: 33011792
Front Med (Lausanne). 2022 Jan 05;8:668995
pubmed: 35071251
Rev Esp Salud Publica. 2021 Oct 22;95:
pubmed: 34675168
Occup Environ Med. 2022 Jun;79(6):388-395
pubmed: 34740981
Addiction. 2021 Jun;116(6):1319-1368
pubmed: 33007104
Ann Intern Med. 2021 May;174(5):649-654
pubmed: 33513035
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Front Immunol. 2020 Jun 11;11:1359
pubmed: 32595653
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nicotine Tob Res. 2021 Aug 4;23(8):1398-1404
pubmed: 33420786
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
J Clin Virol. 2020 Sep;130:104573
pubmed: 32769025
Heart. 2020 Oct;106(19):1503-1511
pubmed: 32737124
C R Biol. 2020 Jun 05;343(1):33-39
pubmed: 32720486
Intern Emerg Med. 2020 Aug;15(5):845-852
pubmed: 32385628
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Int J Epidemiol. 2021 Nov 10;50(5):1458-1472
pubmed: 34293141

Auteurs

Pierre Hausfater (P)

Emergency Department, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université, 83 Boulevard de l'Hôpital, 75651, Paris Cedex 13, France. pierre.hausfater@aphp.fr.
GRC-14 BIOSFAST, UMR INSERM 1166, IHU ICAN, Sorbonne Université, Paris, France. pierre.hausfater@aphp.fr.

David Boutolleau (D)

INSERM, Institut Pierre Louis d'Epidémiologie Et de Santé Publique (iPLESP), GH AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Sorbonne Université, Paris, France.

Karine Lacombe (K)

Infectious Disease Department, Sorbonne Université Hôpital Saint-Antoine, Paris, France.

Alexandra Beurton (A)

Service de Pneumologie-Médecine Intensive Réanimation, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université Inserm UMRS Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.

Margaux Dumont (M)

Emergency Department, Hôpital Pitié-Salpêtrière, APHP, Sorbonne Université, 83 Boulevard de l'Hôpital, 75651, Paris Cedex 13, France.

Jean-Michel Constantin (JM)

Department of Anaesthesiology and Critical Care, GRC 29, AP-HP, DMU DREAM, Hôpital Pitié-Salpêtrière, GH APHP, Sorbonne Université, Paris, France.

Jade Ghosn (J)

AP-HP, Nord, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, and Université de Paris, INSERM, UMR 1137 IAME, Paris, France.

Alain Combes (A)

INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, and Service de Médecine Intensive-Réanimation, Institut de Cardiologie, GH APHP Sorbonne Université Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.

Nicolas Cury (N)

Emergency Department, APHP, Sorbonne Université Hôpital Saint-Antoine, Paris, France.

Romain Guedj (R)

Pediatric Emergency Deparment, APHP Hôpital Armand Trousseau-Sorbonne Université, Faculté de Médecine, Paris, France.
Centre of Research in Epidemiology and Statistics-CRESS, INSERM, Université de Paris, 75004, Paris, France.

Michel Djibré (M)

Service de Médecine Intensive Réanimation, APHP, Sorbonne Université Hôpital Tenon, Paris, France.

Rudy Bompard (R)

Emergency Department, Hôpital Tenon, APHP, Sorbonne Université, Paris, France.

Sandie Mazerand (S)

Service de Médecine Intensive-Réanimation, APHP, Sorbonne Université Hôpital Saint-Antoine, Paris, France.

Valérie Pourcher (V)

AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Service de Maladies Infectieuses et Tropicales, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, 75013, Paris, France.

Linda Gimeno (L)

APHP, Unité de Recherche Clinique Pitié Salpêtrière Charles Foix, Sorbonne Université, 75013, Paris, France.

Clémence Marois (C)

Unité de Médecine Intensive Réanimation Neurologique, Département de Neurologie, DMU Neurosciences, APHP, Sorbonne Université Hôpital Pitié-Salpêtrière, Paris, France.

Elisa Teyssou (E)

INSERM, Institut Pierre Louis d'Epidémiologie Et de Santé Publique (iPLESP), GH AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Sorbonne Université, Paris, France.

Anne-Geneviève Marcelin (AG)

INSERM, Institut Pierre Louis d'Epidémiologie Et de Santé Publique (iPLESP), GH AP-HP, Hôpital Pitié-Salpêtrière, Service de Virologie, Sorbonne Université, Paris, France.

David Hajage (D)

APHP, Unité de Recherche Clinique Pitié Salpêtrière Charles Foix, Sorbonne Université, 75013, Paris, France.
Département de Santé Publique, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Sorbonne Université, CIC-1422, 75013, Paris, France.

Florence Tubach (F)

APHP, Unité de Recherche Clinique Pitié Salpêtrière Charles Foix, Sorbonne Université, 75013, Paris, France.
Département de Santé Publique, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Sorbonne Université, CIC-1422, 75013, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH